Coloplast A/S CLPBY OTC · Healthcare · Denmark
$7.36 -1.66% -$0.12
Summary
68 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It earns 15 DKK a year on every 100 DKK of invested capital.
- Out of every 100 DKK of revenue, 11 DKK is left as net profit.
What to watch
- It pays out more in dividends than it earns: 181% of profit.
- Earnings per share fell by 15% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 36.9 DKK for 1 DKK of yearly profit. Over the last five years it was 34.8 DKK on average.
Valuation in detailIs it growing?
SlowlyRevenue (DKK)
Diluted EPS (DKK)
- Analyst estimate
Revenue grew by 8.5% a year over 5 years. Over the last 3 years it grew by 6.0% a year. For the next fiscal year analysts expect revenue to grow by 7.5%. Earnings per share fell by 15% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 39 DKK
- Research and development 3.7 DKK
- Sales and administration 31 DKK
- Taxes and other 15 DKK
- Net profit 11 DKK
Net profit, industry median (Medical - Instruments & Supplies) 8.5 DKK
Out of every 100 DKK of revenue, 11 DKK is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.91%
- Paid out of profit
- 181%
- Raised in a row
- 3 years
You receive $0.36 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 3
- Sell 2
Today's price within the analysts' price targets
The average target of $7.38 is at today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.